We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.71 | -1.41% | 49.50 | 49.20 | 49.49 | 49.835 | 49.08 | 49.09 | 2,757,444 | 21:34:19 |
From May 2019 to May 2024
By P.R.Venkat
Sanofi India Ltd. (500674.BY) said it is planning to sell a pharmaceutical manufacturing facility in the western Indian state of Gujarat to Zentiva.
Sanofi India, a unit of France-based Sanofi S.A. (SAN.FR), is selling the Ankleshwar site for 2.62 billion Indian rupees ($36.4 million), the company said in a statement on Wednesday.
The Ankleshwar site has a chemistry and biotechnology development centre, and manufactures both intermediates and pharmaceutical formulations. Sanofi's Ankleshwar site manufactures more than six billion tablets annually that include painkiller brands like Combiflam.
Write to venkat.pr@wsj.com
(END) Dow Jones Newswires
September 11, 2019 02:31 ET (06:31 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
